Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF – Research Report), NewAmsterdam Pharma Company (NAMS – Research Report) and Humana (HUM – Research Report).
Sanofi (SNYNF)
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi, with a price target of EUR98.00. The company’s shares closed last Thursday at $95.54.
According to TipRanks.com, Vosser is a 4-star analyst with an average return of
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $112.87, which is a 18.1% upside from current levels. In a report issued on April 25, DZ BANK AG also maintained a Hold rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
NewAmsterdam Pharma Company (NAMS)
Jefferies analyst Dennis Ding assigned a Buy rating to NewAmsterdam Pharma Company on April 27 and set a price target of $45.00. The company’s shares closed last Friday at $21.99.
According to TipRanks.com, Ding is a 3-star analyst with an average return of
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $37.00.
Humana (HUM)
Truist Financial analyst David S Macdonald maintained a Hold rating on Humana today and set a price target of $355.00. The company’s shares closed last Friday at $305.90, close to its 52-week low of $299.23.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Moderate Buy with an average price target of $349.78, implying a 13.1% upside from current levels. In a report issued on April 24, J.P. Morgan also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNYNF:
- Sanofi expects FY24 business EPS to remain relatively stable
- Sanofi reports Q1 IRFS EPS EUR 0.91, down 43.1%
- Previously announced Zantac settlement worth $100M, Bloomber says
- Sanofi to pay $100M to settle Zantac cancer lawsuits, Bloomberg says
- French Stocks: Sanofi (SAN) to Revamp US Vaccine Operations, Trim Jobs
